Virax Biolabs (NASDAQ: VRAX) OKs share surge as charter overhaul fails

Rhea-AI Filing Summary

Virax Biolabs Group Ltd (VRAX) held an Extraordinary General Meeting process in August 2026 to consider changes to its capital structure and governing documents. An initial meeting on August 14, 2026 lacked a quorum and was adjourned to August 21, 2026, where, under the Articles of Association, the shareholders present after 15 minutes (representing 8.94% of voting shares) constituted a quorum.

Shareholders approved an ordinary resolution to increase authorized share capital from US$50,000 (2,000,000 ordinary shares of US$0.025 par value) to US$12,500,000 (500,000,000 ordinary shares), by creating 498,000,000 additional authorized shares. The vote on this Share Capital Increase was 61,471 for, 54,414 against, and 4,342 abstain. A separate special resolution to adopt a fifth amended and restated memorandum and articles of association to reflect the revised authorized share capital and the effective date of a Share Consolidation did not receive the required two-thirds majority and was not approved, despite votes of 66,754 for, 53,203 against, and 270 abstain.

Key Figures

Shares entitled to vote on record date: 1,344,988 ordinary shares Initial meeting attendance: 6.33% of outstanding shares Quorum requirement: Not less than one-third of outstanding shares +6 more

9 metrics

Shares entitled to vote on record date 1,344,988 ordinary shares Shares entitled to be voted at the meeting as of July 27, 2026

Initial meeting attendance 6.33% of outstanding shares Percentage of voting shares present in person or by proxy at the August 14, 2026 meeting

Quorum requirement Not less than one-third of outstanding shares Required quorum under the Articles for a shareholders’ meeting

Adjourned meeting attendance 8.94% of outstanding shares Percentage of voting shares present in person or by proxy at the August 21, 2026 adjourned meeting

Authorized share capital before increase US$50,000 (2,000,000 ordinary shares of US$0.025 par value each) Authorized capital prior to the ordinary resolution

Authorized share capital after increase US$12,500,000 (500,000,000 ordinary shares of US$0.025 par value each) Authorized capital after approval of the Share Capital Increase

Additional authorized shares created 498,000,000 ordinary shares Number of new authorized shares resulting from the Share Capital Increase

Proposal 1 votes 61,471 for; 54,414 against; 4,342 abstain Voting results on the Share Capital Increase ordinary resolution

Proposal 2 votes 66,754 for; 53,203 against; 270 abstain Voting results on the special resolution to adopt fifth amended and restated memorandum and articles

Key Terms

Extraordinary General Meeting, quorum, ordinary resolution, special resolution, +2 more

6 terms

Extraordinary General Meeting regulatory

"convened the Extraordinary General Meeting of Shareholders"

quorum regulatory

"no business shall be transacted at any meeting of shareholders unless a quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

ordinary resolution regulatory

"Shareholders approved, by way of ordinary resolution, the authorized share capital"

An ordinary resolution is a decision made by shareholders at a company meeting that is approved when more than half of the votes cast are in favor. Think of it like a household vote where a majority decides routine matters — it covers everyday corporate actions such as approving directors, routine policy changes, or distributions, and matters to investors because these majority-approved choices shape governance, management authority, and the company’s near-term direction.

special resolution regulatory

"Proposal 2, set out below, which required approval by way of special resolution"

A special resolution is a formal shareholder vote that requires a higher-than-normal majority—typically around three-quarters—to approve major corporate changes, such as altering the company’s governing rules, selling the business, or winding it up. It matters to investors because it signals decisive, potentially value-altering actions that cannot be passed by a simple majority; think of it as needing extra votes to change the rules of a club, so minority interests are harder to override.

authorized share capital financial

"the authorized share capital of the Company be increased"

The maximum number of shares a company is legally allowed to issue according to its governing documents. Think of it as the size of the blank checkbook a company keeps for selling ownership stakes: it sets an upper limit but does not mean all shares are in circulation. Investors care because a larger authorized amount makes it easier for the company to raise money or grant stock-based pay, which can dilute existing holdings and affect control and value per share.

Share Consolidation financial

"with effect from the effective date of the Share Consolidation was not approved"

Share consolidation is a process where a company reduces the total number of its shares by combining multiple existing shares into a smaller number of higher-value shares. This can make each share more expensive and potentially improve the company’s image. For investors, it often means their ownership remains the same, but the value of each share increases, which can influence how the stock is perceived and traded.

FAQ

What did Virax Biolabs (VRAX) shareholders approve at the August 21, 2026 meeting?

Shareholders approved an ordinary resolution to increase authorized share capital from US$50,000 (2,000,000 shares) to US$12,500,000 (500,000,000 shares) of US$0.025 par value, creating 498,000,000 additional authorized ordinary shares.

Did Virax Biolabs (VRAX) adopt the new fifth amended and restated memorandum and articles?

No. The special resolution to adopt the fifth amended and restated memorandum and articles of association was not approved, because it required at least a two-thirds majority of votes cast and did not reach that threshold, despite receiving 66,754 votes for and 53,203 against.

How did Virax Biolabs (VRAX) shareholders vote on the authorized share capital increase?

For the Share Capital Increase, votes were 61,471 for, 54,414 against, and 4,342 abstain. This ordinary resolution passed, authorizing a total of 500,000,000 ordinary shares of US$0.025 par value each.

Why was Virax Biolabs’ (VRAX) August 14, 2026 shareholder meeting adjourned?

On the August 14, 2026 record of 1,344,988 ordinary shares entitled to vote, only 6.33% were present in person or by proxy, below the quorum requirement of at least one-third of outstanding voting shares, so the meeting was adjourned under the Articles.

What was the quorum situation at Virax Biolabs’ (VRAX) August 21, 2026 adjourned meeting?

At the August 21, 2026 adjourned meeting, shareholders present represented 8.94% of outstanding voting shares. Under the Articles, if a one-third quorum is not present within fifteen minutes at an adjourned meeting, shareholders then present constitute a quorum.

What par value do Virax Biolabs (VRAX) ordinary shares carry after the authorized capital increase?

The ordinary shares continue to carry a par value of US$0.025 per share. The change approved was to increase the authorized number of such shares to 500,000,000, resulting in authorized share capital of US$12,500,000.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/26/2026 - 04:31 PM Accepted by SEC EDGAR 08/26/2026 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-41440

Virax Biolabs Group Limited

(Registrant’s Name)

BioCity Glasgow

Bo'Ness Road Newhouse

Lanarkshire, ML1 SUH

United Kingdom

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

When used in this Form 6-K, unless otherwise indicated, the terms “the Company,” “Virax,” “we,” “us” and “our” refer to Virax Biolabs Group Limited. and its subsidiaries.

Information Contained in this Form 6-K Report

Submission of Matters to a Vote of Security Holders.

On August 14, 2026, Virax Biolabs Group Limited (the “Company”) convened the Extraordinary General Meeting of Shareholders (the “Initial Meeting”) commencing at 2:00 PM GMT at BioCity Glasgow, Bo’Ness Road, Newhouse, Lanarkshire, ML1 5UH. On July 27, 2026, the record date for the Annual Meeting, there were 1,344,988 ordinary shares of the Company entitled to be voted at the Annual Meeting, 6.33% of which were present at the Initial Meeting in person or by proxy.

The Company's Articles of Association state that no business shall be transacted at any meeting of shareholders unless a quorum is present; a quorum is one or more shareholders holding shares that represent not less than one-third of the outstanding shares carrying the right to vote at such meeting present in person or by proxy. As such, at the date and time scheduled for the Initial Meeting, there was not a quorum present, nor did a quorum become present within 15 minutes of the scheduled meeting time. In accordance with the Company's amended and restated memorandum and articles of associated then in effect (the "Articles of Association"), if a quorum is not present within fifteen minutes of the time appointed for the meeting, then the meeting shall stand adjourned to the same time and place seven days from then, or to such other time or place as is determined by the Directors. As a quorum was not so present, the Annual Meeting was adjourned to 2:00 PM GMT on August 21, 2026, at the same location.

On August 21, 2026, at 2:00 PM GMT the Company reconvened the Company’s Extraordinary Annual Meeting of Shareholders (the “Adjourned Meeting”) at BioCity Glasgow, Bo’Ness Road, Newhouse, Lanarkshire, ML1 5UH. At the start of the Adjourned Meeting, there were present in person or by proxy shareholders holding shares that represent 8.94% the outstanding shares carrying the right to vote at such meeting. The Company's Articles of Association provide that if a quorum is not present within fifteen minutes of the time appointed for such an adjourned meeting, then the shareholders present in person or by proxy shall constitute a quorum. At the end of such fifteen minutes, a quorum of one-third was not present, and thereafter the shareholders present in person or by proxy constituted a quorum for the Adjourned Meeting.

Two items of business were acted upon by the Company’s shareholders at the Adjourned Annual Meeting, of which Proposal 1 was approved by the shareholders.

1. Shareholders approved, by way of ordinary resolution, the authorized share capital of the Company be increased from US$50,000 divided into 2,000,000 ordinary shares of US$0.025 par value each to US$12,500,000 divided into 500,000,000 ordinary shares of US$0.025 par value each, by the creation of 498,000,000 ordinary shares of US$0.025 par value each (the “Share Capital Increase”); The voting results were as follows:

For		Against		Abstain
61,471		54,414		4,342

2. Proposal 2: Proposal 2, set out below, which required approval by way of special resolution (being the affirmative vote of a majority of at least two-thirds of the votes cast by, or on behalf of, the shareholders entitled to vote at the Meeting either present in person or represented by proxy at the Meeting) was not approved by the shareholders. The adoption of the form of the fifth amended and restated memorandum and articles of association of the Company in the form attached as Exhibit 99.3 filed as part of the Form 6-K report filed on July 31, 2026 containing the Notice of Meeting and Proxy Statement in its entirety and in substitution for, and to the exclusion of, the existing memorandum and articles of association of the Company to reflect the revised authorized share capital, with effect from the effective date of the Share Consolidation was not approved by way of special resolution. The voting results were as follows:

For		Against		Abstain
66,754		53,203		270

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			VIRAX BIOLABS GROUP LIMITED
Date:	August 26, 2026	By:	/s/ James Foster
			James Foster, Chief Executive Officer